BioPath

Latest News
H.C. Wainwright / BPTH: Safety Testing of Phase 2 AML Trial Completed; Financing Closed; Reiterate Buy; Adjusting PT to $25Dec 2 2019
BIO-PATH HOLDINGS ANNOUNCES SUCCESSFUL COMPLETION OF SAFETY TESTING IN STAGE 2 OF PHASE 2 CLINICAL TRIAL IN ACUTE MYELOID LEUKEMIANov 26 2019
BIO-PATH HOLDINGS ANNOUNCES CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR BP1002Nov 21 2019
BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTSNov 15 2019
Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019Nov 8 2019
Bio-Path Holdings Appoints Martina Molsbergen to Board of DirectorsOct 15 2019
Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology PatentSep 25 2019
Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment ConferenceSep 3 2019
Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Acute Myeloid Leukemia TrialAug 26 2019
BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTSAug 15 2019
Bio-Path Holdings to Announce Second Quarter 2019 Financial Results on August 15, 2019Aug 8 2019
BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTSMay 16 2019
Bio-Path Holdings to Announce First Quarter 2019 Financial Results on May 16, 2019May 9 2019
Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019 --- Highlighting Important Cancer Gene, STAT3, Therapeutic Strategy in Pancreatic, Non-Small Cell Lung Cancers and Acute Myelogenous LeukemiaApr 3 2019
BIO-PATH HOLDINGS REPORTS FULL YEAR 2018 FINANCIAL RESULTS: Conference Call to be Held Today at 8:30 a.m. ETMar 20 2019
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019Mar 15 2019
Bio-Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common StockMar 14 2019
Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common StockMar 12 2019
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid LeukemiaMar 6 2019
Bio-Path Holdings to Present Data at the 2019 AACR Annual MeetingFeb 28 2019

More News

Giving Previously Untreatable Cancer Patients a Fighting Chance

We are developing targeted cancer treatments that offer effective therapy without harsh side effects so that even the most fragile patients can have tolerable treatment options.

About Us

DNAbilize^®

The company’s lead candidate is prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, for the treatment of acute myeloid leukemia (AML). Prexigebersen is being assessed in a Phase 2 trial in combination with front-line therapy.

Learn More

Our Patients

Prognosis for these older cancer patients remains very poor. Bio-Path aims to meet the need that exists for non-toxic therapies for older, fragile cancer patients who are unfit or ineligible for high-dose chemotherapy.

A new path in DNA-powered medicine.

Latest News

Giving Previously Untreatable Cancer Patients a Fighting Chance

DNAbilize^®

Our Patients

Our Products

Delivering a Better Path for Cancer Patients.

Latest News

Giving Previously Untreatable Cancer Patients a Fighting Chance

DNAbilize®

Our Patients

Our Products

Delivering a Better Path for Cancer Patients.

DNAbilize^®